Stocky turns companies like Structure Therapeutics Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Structure Therapeutics Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Directors make key decisions about the company; voters approved new leadership for the next three years.
Quarterly earnings show how well the company is doing with its money and operations.
Company raises more money by selling shares, which funds operations and research.
Company raises more money by selling shares, which funds operations and research.
New leadership appointment shows who runs daily operations; experience at Gilead, Myovant signals expertise.
Positive clinical trial results support the company's drug development and future sales potential.
Annual report shows total company performance over the entire year to shareholders and investors.
Stocky reads Structure Therapeutics Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Structure Therapeutics Inc.'s most recent tracked filing was a 8-K on 18 Jun 2026: Shareholders elect three directors through 2029.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.